Two independent preclinical approaches report improved CAR‑T performance: targeting ITK (interleukin‑2‑inducible T‑cell kinase) remodels T‑cell signaling to enhance anti‑CD19 CAR‑T activity, while β‑hydroxybutyrate (BHB), a ketone metabolite, improves CAR‑T metabolic fitness and antitumor potency in mouse models. Both teams present strategies to extend CAR‑T durability and function against resistant malignancies. The ITK work shows kinase modulation can shift T‑cell differentiation and effector programs to favor long‑lived, potent CAR‑T populations, potentially improving outcomes in hematologic cancers. Separately, researchers at the Arc Institute and Stanford found that systemic or ex vivo BHB exposure enhanced CAR‑T expansion and tumor control in murine experiments; human trials are reportedly underway to test safety and translation. CAR‑T therapies rely on engineered T cells that recognize tumor antigens; improving their metabolic and signaling resilience is a key path to broader efficacy and reduced relapse rates. These results support combinatorial strategies—small‑molecule immunomodulation or metabolic priming—alongside genetic engineering to advance CAR‑T therapeutics.